Ritonavir-13C3

Ritonavir-13C3

• CAS Number: 1217673-23-8
• UNSPSC Description: Ritonavir-13C3 is 13C labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM[1].
• Target Antigen: Apoptosis; HIV; HIV Protease; Isotope-Labeled Compounds; SARS-CoV
• Type: Reference compound
• Related Pathways: Anti-infection;Apoptosis;Metabolic Enzyme/Protease;Others
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/ritonavir-13c3.html
• Smiles: CN(C(N[C@@H](C(C)C)C(N[C@H](C[C@@H]([C@@H](NC(O[13CH2][13C]1=[13CH]N=CS1)=O)CC2=CC=CC=C2)O)CC3=CC=CC=C3)=O)=O)CC4=CSC(C(C)C)=N4
• Molecular Weight: 723.92
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Kumar GN, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos. 1999 Aug;27(8):902-8.|[3]Eagling VA, et al. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997 Aug;44(2):190-4.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.|[5]Weichold FF, et al. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 1999 Sep-Oct;2(5):261-9.|[6]Drewe J, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999 May 15;57(10):1147-52.|[7]Kumar GN, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996 Apr;277(1):423-31.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported